USANA Health Sciences Inc (USNA) stock
Close on Nov 16, 2026Market cap $250.17MP/E –Yield –
Earnings
USANA Health Sciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of USANA Health Sciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Jan 3, 2027 | Feb 17, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Oct 3, 2026 | Nov 3, 2026after the close | $206.00M | -3.7% | -$0.30 | -$0.11 | Release |
| Q2 FY2026ended Jul 4, 2026 | Aug 4, 2026after the close | $223.00M | -5.5% | -$1.16 | -$0.07 | Release |
| Q1 FY2026ended Apr 4, 2026 | May 5, 2026after the close | $250.00M | 0.0% | $0.41 | $0.61 | Release |
| Q4 FY2025ended Jan 3, 2026 | Feb 18, 2026after the close | $226.20M | +5.7% | -$0.10 | $0.60 | Release |
| Q3 FY2025ended Sep 27, 2025 | Oct 22, 2025after the close | $214.00M | +7.0% | -$0.36 | -$0.15 | Release |
| Q2 FY2025ended Jun 28, 2025 | Jul 22, 2025after the close | $236.00M | +10.8% | $0.52 | $0.74 | Release |
| Q1 FY2025ended Mar 29, 2025 | Apr 22, 2025after the close | $250.00M | +9.6% | $0.49 | $0.73 | Release |
| Q4 FY2024ended Dec 28, 2024 | Feb 25, 2025after the close | $214.00M | -3.2% | $0.23 | $0.64 | Release |
| Q3 FY2024ended Sep 28, 2024 | Oct 22, 2024after the close | $200.00M | -6.1% | $0.56 | – | Release |
| Q2 FY2024ended Jun 29, 2024 | Jul 23, 2024after the close | $213.00M | -10.5% | $0.54 | – | Release |
| Q1 FY2024ended Mar 30, 2024 | Apr 30, 2024after the close | $228.00M | -8.1% | $0.86 | – | Release |
| Q4 FY2023ended Dec 30, 2023 | Feb 6, 2024after the close | $221.00M | -3.1% | $0.87 | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 24, 2023after the close | $213.00M | -8.6% | $0.59 | – | Release |
| Q2 FY2023ended Jul 1, 2023 | Jul 25, 2023after the close | $238.00M | -9.8% | $0.89 | – | Release |
| Q1 FY2023ended Apr 1, 2023 | Apr 25, 2023after the close | $248.00M | -9.2% | $0.95 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 7, 2023after the close | $228.00M | -14.6% | $0.66 | – | Release |
| Q3 FY2022ended Oct 1, 2022 | Oct 25, 2022after the close | $233.00M | -15.1% | $0.78 | – | Release |
| Q2 FY2022ended Jul 2, 2022 | Jul 26, 2022after the close | $264.00M | – | $1.00 | – | Release |
| Q1 FY2022ended Apr 2, 2022 | Apr 26, 2022after the close | $273.00M | – | $1.15 | – | Release |
| Q4 FY2021ended Jan 1, 2022 | Feb 8, 2022after the close | $267.00M | – | $1.03 | – | Release |
| Q3 FY2021ended Oct 2, 2021 | Oct 26, 2021after the close | $274.40M | – | $1.36 | – | Release |
| Q2 FY2021ended Jul 3, 2021 | Jul 27, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Apr 3, 2021 | Apr 27, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Jan 2, 2021 | Feb 9, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 26, 2020 | Oct 20, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
USANA Health Sciences's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Consolidated net sales | FY2026 | $900.00M | – | New | Nov 3, 2026 |
| Core Nutritional business net sales | FY2026 | $750.00M | $720.00M – $765.00M | Raised | Aug 4, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $87.00M | $101.00M – $109.00M | Lowered | Aug 4, 2026 |
| Adjusted EBITDA (2)non-GAAP | FY2026 | $77.00M | $101.30M – $109.30M | Lowered | Nov 3, 2026 |
| Diluted EPSGAAP | FY2026 | -$0.90 | $1.11 – $1.45 | Lowered | Nov 3, 2026 |
| Diluted EPSGAAP | FY2026 | -$0.61 | $1.11 – $1.45 | Lowered | Aug 4, 2026 |
| Adjusted diluted EPSnon-GAAP | FY2026 | $0.76 | $1.95 – $2.29 | Lowered | Aug 4, 2026 |
| Adjusted diluted EPS(1)non-GAAP | FY2026 | $0.55 | $1.95 – $2.29 | Lowered | Nov 3, 2026 |
| Net (loss) earningsGAAP | FY2026 | -$16.00M | – | Lowered | Nov 3, 2026 |
| Net (loss) earningsGAAP | FY2026 | -$11.00M | – | Lowered | Aug 4, 2026 |
| Net earningsGAAP | FY2026 | $20.00M – $27.00M | – | New | May 5, 2026 |
| Net earningsGAAP | FY2026 | $20.30M – $26.60M | – | New | Feb 18, 2026 |
Guidance history
Every forecast USANA Health Sciences put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 3, 2026 | Adjusted EBITDA (2) | FY2026 | $77.00M | Lowered |
| Nov 3, 2026 | Adjusted diluted EPS(1) | FY2026 | $0.55 | Lowered |
| Nov 3, 2026 | Diluted EPS | FY2026 | -$0.90 | Lowered |
| Nov 3, 2026 | Net (loss) earnings | FY2026 | -$16.00M | Lowered |
| Nov 3, 2026 | Consolidated net sales | FY2026 | $900.00M | New |
| Aug 4, 2026 | Adjusted EBITDA | FY2026 | $87.00M | Lowered |
| Aug 4, 2026 | Adjusted diluted EPS | FY2026 | $0.76 | Lowered |
| Aug 4, 2026 | Diluted EPS | FY2026 | -$0.61 | Lowered |
| Aug 4, 2026 | Net (loss) earnings | FY2026 | -$11.00M | Lowered |
| Aug 4, 2026 | Core Nutritional business net sales | FY2026 | $750.00M | Raised |
| Aug 4, 2026 | Hiya net sales | FY2026 | $125.00M | Lowered |
| Aug 4, 2026 | Rise Wellness net sales | FY2026 | $35.00M | Lowered |
| Aug 4, 2026 | Consolidated net sales | FY2026 | $910.00M | Raised |
| May 5, 2026 | Adjusted EBITDA | FY2026 | $101.00M – $109.00M | New |
| May 5, 2026 | Adjusted diluted EPS | FY2026 | $1.95 – $2.29 | New |
| May 5, 2026 | Diluted EPS | FY2026 | $1.11 – $1.45 | New |
| May 5, 2026 | Net earnings | FY2026 | $20.00M – $27.00M | New |
| May 5, 2026 | Core Nutritional business net sales | FY2026 | $720.00M – $765.00M | New |
| May 5, 2026 | Hiya net sales | FY2026 | $140.00M – $155.00M | Lowered |
| May 5, 2026 | Rise Wellness net sales | FY2026 | $65.00M – $80.00M | Lowered |
| May 5, 2026 | Consolidated net sales | FY2026 | $925.00M – $1.00M | Narrowed |
| Feb 18, 2026 | Adjusted EBITDA (2) | FY2026 | $101.30M – $109.30M | New |
| Feb 18, 2026 | Adjusted Diluted EPS (1) | FY2026 | $1.95 – $2.29 | New |
| Feb 18, 2026 | Diluted EPS | FY2026 | $1.11 – $1.45 | New |
| Feb 18, 2026 | Net earnings | FY2026 | $20.30M – $26.60M | New |
| Oct 22, 2025 | Adjusted EBITDA (2) | FY2025 | $98.00M | Lowered |
| Oct 22, 2025 | Adjusted Diluted EPS (1) | FY2025 | $1.73 | Lowered |
| Oct 22, 2025 | Diluted EPS | FY2025 | $0.78 | Lowered |
| Oct 22, 2025 | Net earnings | FY2025 | $15.00M | Lowered |
| Oct 22, 2025 | Consolidated net sales | FY2025 | $920.00M | New |
| Jul 22, 2025 | Adjusted EBITDA | FY2025 | $107.00M – $123.00M | Reaffirmed |
| Jul 22, 2025 | Adjusted Diluted EPS | FY2025 | $2.35 – $3.00 | Reaffirmed |
| Jul 22, 2025 | Diluted EPS | FY2025 | $1.50 – $2.20 | Reaffirmed |
| Jul 22, 2025 | Effective tax rate | FY2025 | 44% – 45% | Raised |
| Jul 22, 2025 | Net earnings | FY2025 | $29.00M – $41.00M | Reaffirmed |
| Jul 22, 2025 | consolidated net sales growth | FY2025 | +8% – +17% | Lowered |
| Jul 22, 2025 | year-over-year growth | FY2025 | +29% – +42% | Raised |
| Jul 22, 2025 | Net sales from the direct selling business | FY2025 | $775.00M – $840.00M | Raised |
| Jul 22, 2025 | Net sales from Hiya | FY2025 | $145.00M – $160.00M | Lowered |
| Apr 22, 2025 | Adjusted EBITDA | FY2025 | $107.00M – $123.00M | Reaffirmed |
| Apr 22, 2025 | Adjusted Diluted EPS | FY2025 | $2.35 – $3.00 | Reaffirmed |
| Apr 22, 2025 | Diluted EPS | FY2025 | $1.50 – $2.20 | Reaffirmed |
| Apr 22, 2025 | Net earnings | FY2025 | $29.00M – $41.00M | New |
| Apr 22, 2025 | Effective tax rate | FY2025 | 41.5% – 45% | Reaffirmed |
| Apr 22, 2025 | Net sales from the direct selling business | FY2025 | $775.00M – $840.00M | Lowered |
| Apr 22, 2025 | consolidated top line growth | FY2025 | +8% – +17% | Lowered |
| Apr 22, 2025 | Net sales from Hiya year-over-year range | FY2025 | +29% – +42% | Raised |
| Apr 22, 2025 | Consolidated net sales | FY2025 | $920.00M – $1.00B | Raised |
| Apr 22, 2025 | Net sales from Hiya | FY2025 | $145.00M – $160.00M | Lowered |
| Feb 25, 2025 | Adjusted EBITDA (2) | FY2025 | $107.00M – $123.00M | New |
| Feb 25, 2025 | Adjusted Diluted EPS (1) | FY2025 | $2.35 – $3.00 | New |
| Feb 25, 2025 | Diluted EPS | FY2025 | $1.50 – $2.20 | New |
| Feb 25, 2025 | Annualized diluted share count | FY2025 | 19.1 | New |
| Feb 25, 2025 | Effective tax rate | FY2025 | 41.5% – 45% | New |
| Feb 25, 2025 | Net earnings | FY2025 | $29.00M – $41.00M | New |
| Feb 25, 2025 | Consolidated net sales growth | FY2025 | +8% – +17% | New |
| Feb 25, 2025 | Net sales from Hiya year-over-year growth | FY2025 | +29% – +42% | Raised |
| Feb 25, 2025 | Net sales from the USANA business | FY2025 | $775.00M – $840.00M | New |
| Feb 25, 2025 | Net sales from Hiya | FY2025 | $145.00M – $160.00M | Lowered |
| Oct 22, 2024 | diluted EPS | FY2024 | $2.45 | Narrowed |
| Oct 22, 2024 | Consolidated Net Sales | FY2024 | $850.00M | Lowered |
| Jul 23, 2024 | diluted EPS | FY2024 | $2.40 – $2.55 | Lowered |
| Jul 23, 2024 | net sales | FY2024 | $850.00M – $880.00M | Lowered |
| Apr 30, 2024 | diluted EPS | FY2024 | $2.40 – $3.00 | New |
| Apr 30, 2024 | net sales | FY2024 | $850.00M – $920.00M | New |
| Feb 6, 2024 | diluted EPS | FY2024 | $2.40 – $3.00 | New |
| Feb 6, 2024 | operating margin | FY2024 | 8% – 9% | New |
| Feb 6, 2024 | diluted share count | FY2024 | 19.3 | New |
| Feb 6, 2024 | effective tax rate | FY2024 | 38% – 40% | New |
| Feb 6, 2024 | net sales | FY2024 | $850.00M – $920.00M | New |
| Oct 24, 2023 | diluted EPS | FY2023 | $2.80 – $3.05 | Narrowed |
| Oct 24, 2023 | net sales | FY2023 | $900.00M – $920.00M | Lowered |
| Jul 25, 2023 | diluted EPS | FY2023 | $2.65 – $3.30 | New |
| Jul 25, 2023 | net sales | FY2023 | $900.00M – $950.00M | New |
| Apr 25, 2023 | diluted EPS | FY2023 | $2.40 – $3.30 | Raised |
| Apr 25, 2023 | net sales | FY2023 | $875.00M – $950.00M | Raised |
| Feb 7, 2023 | diluted EPS | FY2023 | $2.35 – $3.30 | New |
| Feb 7, 2023 | net sales | FY2023 | $850.00M – $950.00M | New |
| Oct 25, 2022 | diluted EPS | FY2022 | $3.15 – $3.40 | Lowered |
| Oct 25, 2022 | operating cash flow | FY2022 | $80.00M | New |
| Oct 25, 2022 | net sales | FY2022 | $955.00M – $975.00M | Lowered |
| Jul 26, 2022 | diluted EPS | FY2022 | $3.85 – $4.45 | Lowered |
| Jul 26, 2022 | net sales | FY2022 | $1.02B – $1.07B | Lowered |
| Apr 26, 2022 | diluted EPS | FY2022 | $5.00 – $5.70 | Lowered |
| Apr 26, 2022 | net sales | FY2022 | $1.10B – $1.20B | Lowered |
| Feb 8, 2022 | diluted EPS | FY2022 | $5.25 – $6.00 | New |
| Feb 8, 2022 | diluted share count | FY2022 | 19.6 | New |
| Feb 8, 2022 | effective tax rate | FY2022 | 32.5% | New |
| Feb 8, 2022 | net sales | FY2022 | $1.13B – $1.23B | New |
| Oct 26, 2021 | Diluted EPS | FY2021 | $5.80 – $6.00 | New |
| Oct 26, 2021 | free cash flow | FY2021 | $130.00M | New |
| Oct 26, 2021 | Consolidated Net Sales | FY2021 | $1.18B – $1.20B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases USANA Health Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?